TherapeuticsMD analyst ratings
TherapeuticsMD analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/07/2022 | 0.3% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -89.97% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -74.92% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -69.91% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -87.96% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | -49.85% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 50.45% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | -39.82% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 08/14/2018 | 170.81% | Cantor Fitzgerald | $26 → $27 | Maintains | Overweight |
| 06/15/2018 | 10.33% | JP Morgan | → $11 | Initiates Coverage On | → Overweight |
| 09/08/2017 | -39.82% | Morgan Stanley | → $6 | Initiates Coverage On | → Equal-Weight |
| 07/21/2017 | 0.3% | Deutsche Bank | → $10 | Initiates Coverage On | → Buy |
| 07/11/2017 | — | Oppenheimer | Upgrades | Perform → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2022 年 7 月 6 日 | 0.3% | HC Wainwright & Co. | → 10 美元 | 降級 | 買入 → 中性 |
| 2022 年 6 月 5 日 | -89.97% | 坎託·菲茨傑拉德 | 5 美元 → 1 美元 | 降級 | 超重 → 中性 |
| 03/11/2022 | -74.92% | HC Wainwright & Co. | $3 → 2.5 美元 | 維護 | 買 |
| 11/12/2021 | -69.91% | HC Wainwright & Co. | 4 美元 → 3 美元 | 維護 | 買 |
| 08/07/2020 | -87.96% | 傑富瑞集團 | 1.25 美元 → 1.2 美元 | 降級 | 持有 → 表現不佳 |
| 2020 年 5 月 19 日 | — | 摩根大通 | 降級 | 超重 → 中性 | |
| 05/07/2020 | -49.85% | HC Wainwright & Co. | 6 美元 → 5 美元 | 重申 | → 購買 |
| 2020 年 4 月 16 日 | 50.45% | Stifel | 14 美元 → 15 美元 | 維護 | 買 |
| 02/21/2020 | -39.82% | HC Wainwright & Co. | 7 美元 → 6 美元 | 維護 | 買 |
| 08/14/2018 | 170.81% | 坎託·菲茨傑拉德 | 26 美元 → 27 美元 | 維護 | 超重 |
| 06/15/2018 | 10.33% | 摩根大通 | → 11 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 09/08/2017 | -39.82% | 摩根士丹利 | → 6 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 2017 年 7 月 21 日 | 0.3% | 德意志銀行 | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/11/2017 | — | 奧本海默 | 升級 | 表現 → 跑贏大盤 |
TherapeuticsMD Questions & Answers
TherapeuticsMD 問題與解答
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by HC Wainwright & Co. on June 7, 2022. The analyst firm set a price target for $10.00 expecting TXMD to rise to within 12 months (a possible 0.30% upside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2022年6月7日公佈了TherapeuticSMD（納斯達克股票代碼：TXMD）的最新目標股價。該分析公司將目標股價定爲10.00美元，預計TXMD將在12個月內升至12個月內（可能上漲0.30％）。去年有4家分析公司公佈了評級。
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by HC Wainwright & Co., and TherapeuticsMD downgraded their neutral rating.
HC Wainwright & Co. 對TherapeuticSMD（納斯達克股票代碼：TXMD）的最新分析師評級由HC Wainwright & Co. 提供，TherapeuticSMD 下調了中性評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on June 7, 2022 so you should expect the next rating to be made available sometime around June 7, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與TherapeuticSMD的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。TherapeuticSMD的最新評級是在2022年6月7日公佈的，因此您應該預計下一個評級將在2023年6月7日左右公佈。
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a downgraded with a price target of $0.00 to $10.00. The current price TherapeuticsMD (TXMD) is trading at is $9.97, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的TherapeuticSMD（TXMD）評級已下調，目標股價爲0.00美元，至10.00美元。TherapeuticSMD（TXMD）目前的交易價格爲9.97美元，在分析師的預測區間內。